Side effects · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Oral mucositis (moderate to severe) · Adults receiving radiotherapy to the head and neck
Granulocyte-macrophage colony-stimulating factor (GM-CSF), mouthwash showed no clear difference in oral mucositis (moderate to severe) compared with sucralfate mouthwash; GRADE not reported.
1 finding from 1 review
Interruptions to cancer treatment (unscheduled radiotherapy breaks of 5 or more days) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in interruptions to cancer treatment (unscheduled radiotherapy breaks… compared with placebo; GRADE not reported.
1 finding from 1 review
Xerostomia (grade >= 2, 0-3 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Bethanechol led to lower xerostomia (grade >= 2, 0-3 scale) compared with placebo; GRADE not reported.
2 findings from 1 review
Salivary flow rate (stimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Bethanechol showed no clear difference in salivary flow rate (stimulated, ml/min) compared with placebo; GRADE not reported.
1 finding from 1 review
Salivary flow rate (stimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Taste acuity improvement - objective outcome (continuous) - taste recognition (cross-over trial) · Patients with taste disturbances (dysgeusia/hypogeusia; idiopathic, zinc-deficient, or secondary to chronic renal failure)
It is very uncertain whether zinc supplements (zinc sulphate, zinc gluconate, zinc picolinate,… changes taste acuity improvement - objective outcome (continuous) - taste… compared with placebo (very low certainty).
1 finding from 1 review
Oral mucositis (moderate to severe) · Children with acute lymphoblastic leukaemia receiving chemotherapy alone
Keratinocyte growth factor (KGF), intravenous led to lower oral mucositis (moderate to severe) compared with chlorhexidine mouthwash; GRADE not reported.
1 finding from 1 review
Overall survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
It is very uncertain whether amifostine changes overall survival compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Salivary flow rate (unstimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Bethanechol led to higher salivary flow rate (unstimulated, ml/min) compared with placebo; GRADE not reported.
1 finding from 1 review
Survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Survival (locoregional control) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Oral mucositis (any severity) · Adults with cancer receiving treatment
1 finding from 1 review
Oral mucositis (moderate to severe) · Children receiving bone marrow/stem cell transplantation after conditioning therapy for mixed cancers
Granulocyte-colony stimulating factor (G-CSF; pegfilgrastim, single… showed no clear difference in oral mucositis (moderate to severe) compared with granulocyte-colony stimulating factor (G-CSF; filgrastim, multiple…; GRADE not reported.
1 finding from 1 review
Health‐related quality of life · Patients with taste disturbances (dysgeusia/hypogeusia; idiopathic, zinc-deficient, or secondary to chronic renal failure)
1 finding from 1 review
Oral mucositis (severe) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… may leads to lower oral mucositis (severe) compared with placebo (low certainty).
3 findings from 1 review
RR 0.30 [0.14, 0.65]
3 studies · 263 participants
Low
RR 0.85 [0.65, 1.11]
6 studies · 852 participants
Low
RR 0.79 [0.69, 0.90]
3 studies · 471 participants
High
Oral mucositis (severe) · breast cancer patients undergoing chemotherapy
Granulocyte-macrophage colony-stimulating factor (GM-CSF), higher… led to higher oral mucositis (severe) compared with granulocyte-macrophage colony-stimulating factor (GM-CSF), lower…; GRADE not reported.
1 finding from 1 review
Dysphagia · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Palifermin showed no clear difference in dysphagia compared with placebo; GRADE not reported.
1 finding from 1 review
RR 1.32 [0.55, 3.13]
3 studies
GRADE not reported
Locoregional control · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine showed no clear difference in locoregional tumour control compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Disability of oral intake · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Polaprezinc showed no clear difference in disability of oral intake compared with azulene oral rinse; GRADE not reported.
1 finding from 1 review